Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.56 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.51 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.51 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.51 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.51 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.51 |
| ▸ | BRAF | P15056 | 8/20 | 0.48 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.43 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5425952 | 0.93 | MKNK1 (0.54) | MKNK1MKNK2CYP3A4CYP2A6CYP2C9 | |
| SCHEMBL4701573 | 0.87 | HDAC3 (0.48) | MKNK1MKNK2HDAC3HDAC4HDAC1 | |
| SCHEMBL4700617 | 0.87 | CHRNA7 (0.52) | HDAC1HDAC6CHRNA7 | |
| SCHEMBL4700233 | 0.82 | BRAF (0.44) | CYP2C9BRAFCHRNA7CHRNB2CHRNA4 | |
| SCHEMBL4700217 | 0.80 | KDM4E (0.56) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL5419946 | 0.80 | CHRNA7 (0.56) | HDAC1HDAC6CHRNA7 | |
| SCHEMBL4701174 | 0.80 | MKNK1 (0.55) | MKNK1MKNK2CHRNA7 | |
| SCHEMBL4703053 | 0.80 | DYRK1A (0.43) | CYP2C9CHRNA7 | |
| SCHEMBL4700154 | 0.79 | ESRRG (0.43) | CHRNA7 | |
| SCHEMBL4700611 | 0.78 | KMO (0.52) | CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1539765-B1 | BIARYL DIAZABICYCLOALKANE AMIDES AS NICOTINIC ACETYLCHOLINE AGONISTS | ASTRAZENECA AB (SE) | 2008-12-10 | — | — | EP | claimed |
| US-20050239774-A1 | Biaryl diazabicycloalkane amides as nicotinic acetylcholine agonists | ASTRAZENECA AB (SE) | 2005-10-27 | — | — | US | claimed |
| US-20140234270-A1 | TREATMENT WTH ALPHAT SELECTIVE LIGANDS | TARGACEPT, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| EP-2484363-A1 | (2S,3R)-N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-5-methylthiophene-2-carboxamide | Targacept, Inc. (US) | 2012-08-08 | — | — | EP | disclosed |
| EP-2409703-A1 | Treatment with alpha7-selective ligands | Targacept, Inc. (US) | 2012-01-25 | — | — | EP | disclosed |
| US-20110262407-A1 | TREATMENT WITH ALPHA7 SELECTIVE LIGANDS | TARGACEPT, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110124678-A1 | TREATMENT WITH ALPHA 7-SELECTIVE LIGANDS | TARGACEPT, INC. (US) | 2011-05-26 | — | — | US | disclosed |
| EP-2185152-A2 | ALPHA7 NACHR AGONISTS FOR TREATING OR PREVENTING METABOLIC DISORDERS | Targacept Inc. (US) | 2010-05-19 | — | — | EP | disclosed |
| WO-2009018511-A2 | ALPHA7 NACHR AGONISTS FOR TREATING OR PREVENTING METABOLIC DISORDERS | TARGACEPT, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| EP-1539765-B1 | BIARYL DIAZABICYCLOALKANE AMIDES AS NICOTINIC ACETYLCHOLINE AGONISTS | ASTRAZENECA AB (SE) | 2008-12-10 | — | — | EP | disclosed |
| EP-1539765-B1 | BIARYL DIAZABICYCLOALKANE AMIDES AS NICOTINIC ACETYLCHOLINE AGONISTS | ASTRAZENECA AB (SE) | 2008-12-10 | — | — | EP | disclosed |
| US-20050239774-A1 | Biaryl diazabicycloalkane amides as nicotinic acetylcholine agonists | ASTRAZENECA AB (SE) | 2005-10-27 | — | — | US | disclosed |
| EP-1539765-A1 | BIARYL DIAZABICYCLOALKANE AMIDES AS NICOTINIC ACETYLCHOLINE AGONISTS | AstraZeneca AB (SE) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004016617-A1 | BIARYL DIAZABICYCLOALKANE AMIDES AS NICOTINIC ACETYLCHOLINE AGONISTS | ASTRAZENECA AB (SE) | 2004-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140234270-A1 | TREATMENT WTH ALPHAT SELECTIVE LIGANDS | CHRNA7, CHRNA2, CHRNA4 | MKNK1 2224/4885MKNK2 2044/4885CYP3A4 4599/4885 |
| US-20110124678-A1 | TREATMENT WITH ALPHA 7-SELECTIVE LIGANDS | CHRNA7, CHRNA1, CHRNG | MKNK1 2912/4885MKNK2 2550/4885CYP3A4 1379/4885 |
| US-20050239774-A1 | Biaryl diazabicycloalkane amides as nicotinic acetylcholine agonists | CHRNA1, CHRNB1, CHRNA2 | MKNK1 3267/4885MKNK2 2588/4885CYP3A4 727/4885 |
| US-20110262407-A1 | TREATMENT WITH ALPHA7 SELECTIVE LIGANDS | CHRNA7, CHRNA4, CHRNA2 | MKNK1 1964/4885MKNK2 1496/4885CYP3A4 4448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.